Immunotoxicity of epicutaneously applied anticoagulant rodenticide warfarin: evaluation by contact hypersensitivity to DNCB in rats.
The immunotoxicity of epicutaneously administered anticoagulant rodenticide warfarin (WF) was examined in this work by using experimental contact hypersensitivity (CHS) reaction to hapten dinitrochlorobenzene (DNCB). WF (0.05 and 0.5 mg/kg) administration 24 h before the induction of CHS does not change expression of CHS evaluated by ear swelling assay. Regional draining lymph node response during sensitization phase was characterized by decreased cellularity but increased spontaneous and IL-2 stimulated proliferation of draining lymph node cells (DLC). No changes in IL-2 production and in numbers of CD25(+) cells were noted and even decreased proliferative index (ratio of IL-2 stimulated to unstimulated DLC proliferation) was detected. Increase in granulocyte activity (MTT reduction and adhesion to plastic) was noted following application of WF solely with further increase following subsequent application of DNCB, when granulocyte activation (NBT reduction) was noted also. Access of WF into general circulation might be responsible for observed changes, what was supported by ex vivo changes in DLC and granulocyte functions assessed before initiation of sensitization and by in vitro effect of exogenous WF as well. Differential effects of WF on lymphocytes and granulocytes noted in this study highlight the need for simultaneous testing of both cell type activity what might constitute a more integrated approach in immunotoxicity studies.
Institute for Medical Research, Military Medical Academy, Crnotravska 17, 11000, Belgrade, Yugoslavia. dragan@ibiss.bg.ac.yu
Milena
M
Kataranovski
Marija
M
Vlaski
Dragan
D
Kataranovski
Natasa
N
Tosić
Slavka
S
Mandić-Radić
Vera
V
Todorović
D000287:Administration, Topical; D000818:Animals; D000925:Anticoagulants / Q000008:administration & dosage / Q000276:immunology / Q000633:toxicity*; D002448:Cell Adhesion / Q000276:immunology; D003877:Dermatitis, Contact / Q000209:etiology* / Q000276:immunology; D004137:Dinitrochlorobenzene / Q000276:immunology / Q000633:toxicity*; D005562:Formazans / Q000378:metabolism; D006098:Granulocytes / Q000276:immunology / Q000378:metabolism; D007376:Interleukin-2 / Q000276:immunology / Q000378:metabolism; D007509:Irritants / Q000276:immunology / Q000633:toxicity*; D008198:Lymph Nodes / Q000276:immunology / Q000378:metabolism; D008213:Lymphocyte Activation / Q000276:immunology; D008297:Male; D010314:Partial Thromboplastin Time; D011517:Prothrombin Time; D051381:Rats; D015375:Receptors, Interleukin-2 / Q000276:immunology / Q000378:metabolism; D012378:Rodenticides / Q000008:administration & dosage / Q000276:immunology / Q000633:toxicity*; D013778:Tetrazolium Salts / Q000378:metabolism; D014859:Warfarin / Q000008:administration & dosage / Q000276:immunology / Q000633:toxicity*
D000925:Anticoagulants; D004137:Dinitrochlorobenzene; D005562:Formazans; D007376:Interleukin-2; D007509:Irritants; D015375:Receptors, Interleukin-2; D012378:Rodenticides; D013778:Tetrazolium Salts; C079782:MTT formazan; D014859:Warfarin